Innoviva (INVA) Operating Margin (2011 - 2026)
Innoviva (INVA) posted Operating Margin of 38.94% for Q1 2026, up 103.06% on a QoQ basis from 1274.01% in Q4 2025, and down 781.0% year-over-year from 5.72% in Q1 2025.
Innoviva (INVA) Operating Margin (2011 - 2026) Analysis & Trends
Innoviva's Operating Margin history runs 16 years deep, the most recent figure standing at 38.94% for Q1 2026.
- Quarterly Operating Margin fell 781.0% year-over-year to 38.94% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 39.88% (down 595.0% YoY) and the FY2025 annual result came in at 39.81%, down 671.0% from the prior year.
- Operating Margin was 38.94% for Q1 2026 at Innoviva, up from 1274.01% in the prior quarter.
- Across five years, Operating Margin topped out at 58.45% in Q3 2023 and bottomed at 1274.01% in Q4 2025.
- A 5-year average of 434.34% and a median of 430.5% in 2023 frame the typical range for Operating Margin.
- Annual changes were most pronounced in 2022 — Operating Margin slumped 411120 bps — and 2024, when it surged 116203 bps.
- Innoviva's Operating Margin stood at 982.68% in 2022, then jumped by 56 bps to 430.5% in 2023, then plunged by 98 bps to 853.36% in 2024, then tumbled by 49 bps to 1274.01% in 2025, then surged by 103 bps to 38.94% in 2026.
- Business Quant data shows INVA's Operating Margin at 38.94% in Q1 2026, 1274.01% in Q4 2025, and 42.05% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Innoviva | 1.57 Bn | 969.11 Mn | 75.83 Mn | 38.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.94% |
| Dec 31, 2025 | -1,274.01% |
| Sep 30, 2025 | 42.05% |
| Jun 30, 2025 | 48.61% |
| Mar 31, 2025 | 46.74% |
| Dec 31, 2024 | -853.36% |
| Sep 30, 2024 | 46.36% |
| Jun 30, 2024 | 54.74% |
| Mar 31, 2024 | -673.86% |
| Dec 31, 2023 | -430.50% |
| Sep 30, 2023 | 58.45% |
| Jun 30, 2023 | -1,107.29% |
| Mar 31, 2023 | -1,173.47% |
| Dec 31, 2022 | -982.68% |
| Sep 30, 2022 | 27.00% |
| Jun 30, 2022 | -585.27% |
| Mar 31, 2022 | -666.20% |
| Dec 31, 2021 | -611.53% |
| Sep 30, 2021 | 95.21% |
| Jun 30, 2021 | 3,525.93% |